The role of molecular testing in pancreatic cancer
| Autor: | David B. Zhen, Rachael A. Safyan, Eric Q. Konick, Ryan Nguyen, Colin C. Prichard, E. Gabriela Chiorean |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Gastroenterology, Vol 16 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1756-2848 17562848 |
| DOI: | 10.1177/17562848231171456 |
| Popis: | Pancreatic ductal adenocarcinoma (PDA) is highly aggressive and has few treatment options. To personalize therapy, it is critical to delineate molecular subtypes and understand inter- and intra-tumoral heterogeneity. Germline testing for hereditary genetic abnormalities is recommended for all patients with PDA and somatic molecular testing is recommended for all patients with locally advanced or metastatic disease. KRAS mutations are present in 90% of PDA, while 10% are KRAS wild type and are potentially targetable with epidermal growth factor receptor blockade. KRAS G12C inhibitors have shown activity in G12C-mutated cancers, and novel G12D and pan-RAS inhibitors are in clinical trials. DNA damage repair abnormalities, germline or somatic, occur in 5–10% of patients and are likely to benefit from DNA damaging agents and maintenance therapy with poly-ADP ribose polymerase inhibitors. Fewer than 1% of PDA harbor microsatellite instability high status and are susceptible to immune checkpoint blockade. Albeit very rare, occurring in |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|